共 232 条
[1]
Ando K(2021)Recent developments in cancer research: expectations for a new remedy Ann Gastroenterol Surg 5 419-26
[2]
Hu Q(2023)Emerging evidence of immunotherapy for colorectal cancer Ann Gastroenterol Surg 7 216-24
[3]
Kasagi Y(2023)Updated immunotherapy for gastric cancer J Clin Med 12 2636-71
[4]
Oki E(2017)Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 390 2461-43
[5]
Mori M(2021)Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) Esophagus 18 835-47
[6]
Miyamoto Y(2022)Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 23 234-40
[7]
Ogawa K(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet. 398 27-62
[8]
Ohuchi M(2022)Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma N Engl J Med 386 449-71
[9]
Tokunaga R(2021)Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Lancet 398 759-17
[10]
Baba H(2019)Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 20 1506-8